Literature DB >> 19287157

Sulfotransferase gene copy number variation: pharmacogenetics and function.

S J Hebbring1, A M Moyer, R M Weinshilboum.   

Abstract

Pharmacogenetics is the study of the role of inheritance in variation to drug response. Drug response phenotypes can vary from adverse drug reactions at one end of the spectrum to equally serious lack of the desired effect of drug therapy at the other. Many of the current important examples of pharmacogenetics involve inherited variation in drug metabolism. Sulfate conjugation catalyzed by cytosolic sulfotransferase (SULT) enzymes, particularly SULT1A1, is a major pathway for drug metabolism in humans. Pharmacogenetic studies of SULT1A1 began over a quarter of a century ago and have advanced from biochemical genetic experiments to include cDNA and gene cloning, gene resequencing, and functional studies of the effects of single nucleotide polymorphisms (SNPs). SNP genotyping, in turn, led to the discovery of functionally important copy number variations (CNVs) in the SULT1A1 gene. This review will briefly describe the evolution of our understanding of SULT1A1 pharmacogenetics and CNV, as well as challenges involved in utilizing both SNP and CNV data in an attempt to predict SULT1A1 function. SULT1A1 represents one example of the potential importance of CNV for the evolving disciplines of pharmacogenetics and pharmacogenomics. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287157      PMCID: PMC2920188          DOI: 10.1159/000184710

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  37 in total

Review 1.  Sulfotransferases in the bioactivation of xenobiotics.

Authors:  H Glatt
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

2.  An overview of bioactivation of chemical carcinogens.

Authors:  H R Glatt
Journal:  Biochem Soc Trans       Date:  2000-02       Impact factor: 5.407

Review 3.  A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily.

Authors:  Rebecca L Blanchard; Robert R Freimuth; Jochen Buck; Richard M Weinshilboum; Michael W H Coughtrie
Journal:  Pharmacogenetics       Date:  2004-03

4.  Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies.

Authors:  R R Freimuth; B Eckloff; E D Wieben; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  2001-12

Review 5.  Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects.

Authors:  H Glatt; H Boeing; C E Engelke; L Ma; A Kuhlow; U Pabel; D Pomplun; W Teubner; W Meinl
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

6.  Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies.

Authors:  Michelle A T Hildebrandt; Oreste E Salavaggione; Yvette N Martin; Heather C Flynn; Syed Jalal; Eric D Wieben; Richard M Weinshilboum
Journal:  Biochem Biophys Res Commun       Date:  2004-09-03       Impact factor: 3.575

7.  Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes.

Authors:  R R Freimuth; M Wiepert; C G Chute; E D Wieben; R M Weinshilboum
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

Review 8.  Pharmacogenetics of soluble sulfotransferases (SULTs).

Authors:  Hansruedi Glatt; Walter Meinl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-05       Impact factor: 3.000

9.  Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics.

Authors:  Araba A Adjei; Bianca A Thomae; Janel L Prondzinski; Bruce W Eckloff; Eric D Wieben; Richard M Weinshilboum
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

10.  Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism.

Authors:  Bianca A Thomae; Oktay F Rifki; Michelle A Theobald; Bruce W Eckloff; Eric D Wieben; Richard M Weinshilboum
Journal:  J Neurochem       Date:  2003-11       Impact factor: 5.372

View more
  16 in total

1.  Multi-ethnic SULT1A1 copy number profiling with multiplex ligation-dependent probe amplification.

Authors:  Raymon Vijzelaar; Mariana R Botton; Lisette Stolk; Suparna Martis; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-05-23       Impact factor: 2.533

2.  Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.

Authors:  Stuart A Scott; Manishkumar Patel; Suparna Martis; Steven A Lubitz; Sarina van der Zee; Chang Yoo; Lisa Edelmann; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2011-12-21       Impact factor: 2.533

3.  Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression.

Authors:  Roman Tremmel; Kathrin Klein; Florian Battke; Sarah Fehr; Stefan Winter; Tim Scheurenbrand; Elke Schaeffeler; Saskia Biskup; Matthias Schwab; Ulrich M Zanger
Journal:  Hum Genet       Date:  2019-11-30       Impact factor: 4.132

4.  Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease.

Authors:  N J Butcher; M K Horne; G D Mellick; C J Fowler; C L Masters; R F Minchin
Journal:  Pharmacogenomics J       Date:  2017-04-04       Impact factor: 3.550

5.  Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Authors:  Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

6.  Inferring causal genomic alterations in breast cancer using gene expression data.

Authors:  Linh M Tran; Bin Zhang; Zhan Zhang; Chunsheng Zhang; Tao Xie; John R Lamb; Hongyue Dai; Eric E Schadt; Jun Zhu
Journal:  BMC Syst Biol       Date:  2011-08-01

7.  Copy number polymorphisms and anticancer pharmacogenomics.

Authors:  Eric R Gamazon; R Stephanie Huang; M Eileen Dolan; Nancy J Cox
Journal:  Genome Biol       Date:  2011-05-25       Impact factor: 13.583

Review 8.  Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.

Authors:  Gurusamy Umamaheswaran; Dhakchinamoorthi Krishna Kumar; Chandrasekaran Adithan
Journal:  Indian J Med Res       Date:  2014-01       Impact factor: 2.375

9.  The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors.

Authors:  Lena Secky; Martin Svoboda; Lukas Klameth; Erika Bajna; Gerhard Hamilton; Robert Zeillinger; Walter Jäger; Theresia Thalhammer
Journal:  J Drug Deliv       Date:  2013-02-13

10.  Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma.

Authors:  Bo Peng; Yixue Gu; Yan Xiong; Guopei Zheng; Zhimin He
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.